Stanford School of Medicine

stanford-som

In conjunction with the Stanford University School of Medicine, BERG is involved in a Phase I/II monotherapy clinical trial for its drug candidate BPM 31510-IV for the potential treatment of glioblastoma multiforme, a rare and deadly brain cancer.